In silico Identification of Key Genes and Repurposable Drugs for Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) is a highly aggressive and treatment-resistant subtype, lacking HER2, progesterone, and estrogen receptors. Systemic chemotherapy remains the primary treatment due to the absence of molecular targets, often leading to poor prognosis and high recurrence. This study used an integrated...